LONDON (IT BOLTWISE) – AstraZeneca shares are showing a slight upward trend in London trading, reaching a price of GBP 137.04. Analysts expect a further increase as the company reports its financial results for the third quarter of 2025. The stock is nearing its 52-week high, indicating strong investor confidence.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
AstraZeneca shares made a notable rise in London trading, reaching £137.04. This development comes as the company has reported its financial results for the third quarter of 2025. Analysts are optimistic, predicting a further rise in the share price as it nears its 52-week high of £138.84.
Compared to the same quarter last year, AstraZeneca recorded a sales increase of 7.98 percent, driven by a strong drug pipeline and successful market strategies. Revenue was £11.27 billion, while earnings per share (EPS) rose to £1.22 from £0.71 a year ago. These positive numbers reflect investor confidence and could further boost the share price.
Analysts expect earnings per share of $9.18 for 2025, indicating continued positive development for the company. The average price target is £145.86, signaling further growth potential. These expectations are based on AstraZeneca’s strong drug development performance and successful implementation of cost reduction measures.
AstraZeneca shares also benefit from an agreement with the US government that provides for a tariff reduction to reduce drug prices. This agreement could strengthen the company’s competitiveness in the US market and open up additional growth opportunities. The release of fourth quarter 2025 financial results is expected on February 5, 2026 and could provide further insight into AstraZeneca’s future performance.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “AstraZeneca: price increase and analyst expectations in focus”.